Moderna vaccine added to COVID-19 booster arsenal

The provisional tick for the mRNA vaccine comes as UK data show heterologous schedules are ‘non-inferior’

A major study shows a booster dose of Moderna’s mRNA COVID-19 vaccine in a heterologous schedule increases immunogenicity compared with a homologous regime.

Neutralising antibodies are lower, however, with use of the Novavax protein-based vaccine as a booster.